Want to see RNXT full AI Analyst Report?
RNXT Stock Chart & Stats
$1.42
$0.08(9.14%)
At close: 4:00 PM EDT
$1.42
$0.08(9.14%)
Day’s Range― - ―
52-Week Range$0.70 - $2.59
Previous CloseN/A
Volume351.25K
Average Volume (3M)1.20M
Market Cap
$76.27M
Enterprise Value$37.26
Total Cash (Recent Filing)$9.48M
Total Debt (Recent Filing)$259.00K
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 16, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding45,129,510
10 Day Avg. Volume959,927
30 Day Avg. Volume1,201,845
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.13Price Target Upside401.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$3.65M
Bulls Say, Bears Say
Bulls Say
Rapid Commercial Expansion And Revenue GrowthRapid revenue growth alongside expanding commercial-center adoption indicates that RenovoRx is converting its platform into recurring clinical use. A larger installed base and growing site funnel can support durable revenue expansion as repeat procedures and new activations compound.
Strong Gross Margins And Underlying Unit EconomicsGross margins near 84% suggest the commercial offering has attractive economics before corporate operating costs. If RenovoRx sustains this margin profile while increasing procedure volume, incremental revenue could contribute meaningfully toward narrowing losses and funding growth.
Phase 3 Clinical Progress And Broader Adoption PotentialCompletion of Phase 3 enrollment advances the lead program toward an important evidence milestone, while sarcoma use shows potential expansion beyond pancreatic cancer. Together, these developments can broaden clinical credibility and the platform's addressable applications.
Bears Say
Large Ongoing Losses And Persistent Cash BurnThe company is not yet self-financing: substantial operating and free-cash-flow deficits require continued use of cash or external capital. Persistent losses can constrain investment flexibility and may pressure the business to raise funding before reaching sustainable operating scale.
Breakeven Depends On Rapid Commercial ScalingThe path to cash-flow breakeven depends on converting the commercial pipeline quickly and generating repeat utilization from activated sites. If adoption develops more slowly, operating expenses could continue outpacing revenue and extend the period of external funding dependence.
Clinical Validation Remains Pending And Timing-sensitiveAlthough enrollment is complete, the lead program still requires remaining events and a later topline readout before its clinical value is fully validated. Delays or unfavorable results could slow physician adoption, commercialization, and the company's broader growth strategy.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $2.59 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $76.27M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Nov 16, 2026 which is in 56 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on Aug 12, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.072 by $0.012.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.06.
How many shares outstanding does RenovoRx have?
RenovoRx has 45,129,510 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.072. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.13 (401.76% Upside)
$7.13 (401.76% Upside)
Blogger Sentiment
Bullish
RNXT Sentiment 67%
Sector Average 63%
Sector Average 63%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 22.0%
Last 30 Days ▲ 22.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
RenovoRx
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RNXT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial commercial and clinical progress: record revenue with strong sequential and year-over-year growth, expanding active sites and a robust pipeline, completion of phase 3 enrollment, high gross margins, and improving adjusted operating loss. Key risks highlighted include continued operating losses and high SG&A relative to current revenue, declining cash to $9.5M and dependence on rapid site conversions and remaining clinical events to achieve the projected revenue run rate and breakeven timeline. On balance, the call conveyed positive execution and momentum with identifiable near-term operational and timing risks.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$7.13
▲(401.76% Upside)
Technical Analysis
Immutep
―
Karyopharm Therapeutics
―
TScan Therapeutics
―
Xilio Therapeutics
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
3.70% Insiders
3.91% Mutual Funds
14.25% Other Institutional Investors
74.63% Public Companies and
Individual Investors